Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata, Niigata, 951-8510, Japan.
Mod Rheumatol. 2013 Jan;23(1):172-4. doi: 10.1007/s10165-012-0629-6. Epub 2012 Mar 25.
A 36-year-old woman was diagnosed with systemic lupus erythematosus (SLE). Seven days after beginning glucocorticoid treatment, she developed reduced visual acuity, and atypical severe central serous chorioretinopathy (CSC) was confirmed. Since glucocorticoid use is an important risk factor for CSC, the PSL was reduced, tacrolimus was added, and the visual acuity improved rapidly. Reduction in glucocorticoid combined with the use of immunosuppressive agents is one option for preventing a deterioration in atypical severe CSC while still controlling SLE.
一位 36 岁女性被诊断患有系统性红斑狼疮 (SLE)。开始糖皮质激素治疗 7 天后，她出现视力下降，并确诊为非典型性重度中心性浆液性脉络膜视网膜病变 (CSC)。由于糖皮质激素的使用是 CSC 的一个重要危险因素，因此减少了 PSL（泼尼松龙）的剂量，加用了他克莫司，视力迅速改善。减少糖皮质激素联合使用免疫抑制剂是预防控制 SLE 的同时，防止非典型性重度 CSC 恶化的一种选择。
